- Home
- QNRX vs SCNI Comparison
QNRX vs SCNI Comparison
Compare QNRX & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- SCNI
- Stock Information
- Founded
- QNRX 2018
- SCNI 2003
- Country
- QNRX United States
- SCNI Israel
- Employees
- QNRX N/A
- SCNI N/A
- Industry
- QNRX Medical/Dental Instruments
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QNRX Health Care
- SCNI Health Care
- Exchange
- QNRX Nasdaq
- SCNI Nasdaq
- Market Cap
- QNRX 3.3M
- SCNI 1.9M
- IPO Year
- QNRX N/A
- SCNI N/A
- Fundamental
- Price
- QNRX $6.26
- SCNI $2.80
- Analyst Decision
- QNRX
- SCNI
- Analyst Count
- QNRX 0
- SCNI 0
- Target Price
- QNRX N/A
- SCNI N/A
- AVG Volume (30 Days)
- QNRX 44.8K
- SCNI 22.4K
- Earning Date
- QNRX 05-13-2025
- SCNI 07-01-2025
- Dividend Yield
- QNRX N/A
- SCNI N/A
- EPS Growth
- QNRX N/A
- SCNI N/A
- EPS
- QNRX N/A
- SCNI 5.95
- Revenue
- QNRX N/A
- SCNI $658,000.00
- Revenue This Year
- QNRX N/A
- SCNI N/A
- Revenue Next Year
- QNRX N/A
- SCNI N/A
- P/E Ratio
- QNRX N/A
- SCNI $0.47
- Revenue Growth
- QNRX N/A
- SCNI N/A
- 52 Week Low
- QNRX $5.01
- SCNI $1.90
- 52 Week High
- QNRX $54.95
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- QNRX 42.24
- SCNI 57.37
- Support Level
- QNRX $6.05
- SCNI $2.64
- Resistance Level
- QNRX $7.09
- SCNI $2.69
- Average True Range (ATR)
- QNRX 0.74
- SCNI 0.21
- MACD
- QNRX 0.15
- SCNI 0.09
- Stochastic Oscillator
- QNRX 41.50
- SCNI 84.27
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.